Los Angeles Convention Center
Los Angeles, CA
May 16-20, 2023

Explore the latest developments in Cell and Gene Therapy with MilliporeSigma.

Please join our speaking sessions below;

Industry Symposium 

Title - Industry Experts Conversations with Avid Bioservices, Center for Breakthrough Medicines & Capsida Biotherapeutics

Gene Therapy Manufacturing: Science, Scale-Up, Stories and Success (12:00pm – 1:30p,)

  • The Sf-RVN® Platform Applied to Baculovirus Infected Insect Cells (BIIC) (12:00pm – 12:15pm)
  • A Rapid Path to Viral Vector Manufacturing using the VirusExpress® Production Platform (12:15pm – 12:30pm)
  • Pellicon® Capsules versus Hollow Fibers for Ultrafiltration/Diafiltration (UF/DF) in Viral Gene Therapy Manufacturing (12:30pm – 12:45pm)
  • Chromatography Solutions for AAV Full and Empty Capsid Separation (12:45pm – 1:00pm)
  • Industry Experts Conversations with Avid Bioservices, Center for Breakthrough Medicines & Capsida Biotherapeutics (1:00pm – 1:30pm)

Tools & Tech forum

Next Generation Sequencing to characterize encapsidated residual nucleic acids in AAV manufacturing

presented by Brad Hasson, Director of Lab Operations for NGS Services

Exhibitor Showcase

Utilization of DoE for AAV Process Development

presented by Michael Shen, PhD, Head of Viral Vector Process Development.

From solving your unique upstream and downstream challenges, to meeting urgent manufacturing timelines, and navigating uncertain regulatory guidelines, our 30+ years of global expertise integrating leading manufacturing technologies with process development, scale-up,  product characterization and safety testing is here to help you accelerate your path to cures. Draw on our experience to bring your cell and gene therapies to life. MilliporeSigma is the U.S. and Canada Life Science business of Merck KgaA, Darmstadt, Germany.


 Videos

The Sf-RVN® Platform
CTDMO Viral Vector Services VIDEO

 Products

  • BioReliance® Product Characterization
    It is imperative to understand product and process consistency and mitigate risk as related to safety and efficacy. We employ both classic and progressive techniques to evaluate these ICH Q6B driven Critical Quality Attributes.
    ...

  • BioReliance® Product Characterization and Analytical Development Services

    It is imperative to understand product and process consistency and mitigate risk as related to safety and efficacy. We employ both classic and progressive techniques to evaluate these ICH Q6B driven Critical Quality Attributes. 

  • BioReliance® Biosafety Testing Services
    We offer exceptional, risk-mitigating solutions with technical and regulatory expertise. Whatever stage of you’re in, our leading cGMP-compliant testing services and regulatory knowledge can help you progress your therapeutic from discovery to release....

  • BioReliance® Biosafety Testing Services

    We offer exceptional, risk-mitigating solutions with technical and regulatory expertise.  Whatever stage of you’re in, our leading cGMP-compliant testing services and regulatory knowledge can help you progress your therapeutic from discovery to release.

  • The Sf-RVN® Platform
    The Sf-RVN® Platform: a rhabdovirus-free platform that improves the safety profile of your gene therapy....

  • The Sf-RVN® Platform: a rhabdovirus-free platform that improves the safety profile of your gene therapy.

    The baculovirus-insect cell system is widely used for production of recombinant proteins and clinical stage AAV due to its flexibility, speed, simplicity, and productivity. With the Sf-RVN® Platform, we provide a rhabdovirus-free cell line that improves the safety profile of your bioprocesses combined with a chemically defined medium specifically formulated to get excellent growth and productivity while adhering to evolving regulatory requirements.

  • VirusExpress® Production Platform
    The VirusExpress® Production Platform offers a transfection-based solution to lentivirus (LV) or adeno-associated virus (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and production process....

  • This platform can enable you to dramatically reduce the time in process development and scale-up. Whether performed in your facilities or leveraging our gene therapy CDMO capabilities, you can draw on our 30+ years of viral vector manufacturing experience and a platform that can dramatically reduce your process development and scale-up time to speed your therapy to patients. 

  • Cellvento® 4HEK medium
    With our new Cellvento® 4HEK medium, you can produce higher AAV titers across multiple HEK293 cell lines...

  • With our new Cellvento® 4HEK medium, you can produce higher AAV titers across multiple HEK293 cell lines, maximize production of full capsids of AAV, support robust cell growth, facilitate transfection of multiple HEK293 lineages, and thus saves you time in bringing your gene therapy to life!

    • Optimized for AAV Production
      • Enables high AAV titers of full AAV capsids
    • Multiple HEK293 Lineages
      • Supports robust growth and AAV productivity of multiple HEK293 cell lines
    • One Formula for the Entire Process
      • Easy-to-use medium for all stages like growth, transfection and production
  • Benzonase® endonuclease Safety Plus
    The use of Benzonase® endonuclease can significantly reduce the levels of DNA by more than 100,000-fold while also reducing viscosity and protecting downstream equipment from DNA fouling....

    1. Benzonase® endonuclease Safety Plus

    The use of Benzonase® endonuclease can significantly reduce the levels of DNA by more than 100,000-fold while also reducing viscosity and protecting downstream equipment from DNA fouling. However, optimization strategies and DoE are critical when it comes to reducing DNA in your process. Setting up a DoE for your Benzonase® endonuclease application can help you find the optimal operation conditions that deliver the required DNA clearance from your process.

    •        Intensifies downstream processes

    Increased efficiency

    Higher recovery

    •        Helps meet regulatory expectations

  • Pellicon® Capsule for VGT
    Our Pellicon® Capsules are a true single-use solution for your TFF challenges. Designed for efficient single-use UF/DF, the Pellicon® Capsule is a first-of-its-kind spiral-wound TFF filter...

  • Our Pellicon® Capsules are a true single-use solution for your TFF challenges. Designed for efficient single-use UF/DF, the Pellicon® Capsule is a first-of-its-kind spiral-wound TFF filter engineered to provide you with performance consistency and linear scalability for reliable process development and predictable scale-up at any stage of your gene therapies and vaccines.  Its plug ‘n play holderless format provides fast and easy installation, as well as self-containment for those processes requiring additional safety. The capsules are gamma sterilized and can integrate into our TFF systems from process development to process scale. With optimum feed channel design, the capsules perform with high flux to meet your concentration targets with speed.